The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.
Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial 3'RNA sequencing was performed in 1,733 ...
A new "tumor-on-a-chip" model is giving scientists a live look at how pancreatic cancer can recruit the body's own immune ...
Abstract:Cancer cells depend on coordinated changes in metabolism and epigenetic regulation to sustain growth, divide under stress, and adapt to therapy.
Your doctor will check your blood at regular intervals during treatment. When you start taking these medications, your doctor may do blood tests once every two weeks. After the first couple of visits, ...
In 2016, Colinda Scheele, a cancer biologist at Catholic University Leuven, was studying how chemotherapy affects breast cancer cells in mice. However, she observed an inconsistency: Some cell ...
Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat ...
The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results